TVM Capital: Funding, Team & Investors

Loading organizations...

TVM Capital: Funding, Team & Investors | Startup Intros

About

TVM Capital Life Science is a venture capital firm investing in innovative life science companies. It provides capital and expertise to develop and market products poised to transform medical practice. The firm uses an asset-centric, capital-efficient investment strategy, primarily targeting early-stage therapeutics and future leaders across diverse life science segments.

Founded in 1983 as Techno Venture Management, the firm exclusively focused on life sciences from 2012. Managing Partners Dr. Hubert Birner and Stefan Fischer, both joining in 2000, significantly shaped this transition. Their backgrounds in medicine, pharmaceutical development, and finance established the specialized industry insight central to the firm's investment approach.

TVM Capital Life Science partners with entrepreneurs and companies creating novel therapies and medical technologies. Its mission is to improve patient care by funding innovations addressing critical unmet medical needs. The firm cultivates portfolio company success, aiming for both impactful health advancements and strong investor returns through strategic life science investments.

Investment Activity

TVM Capital has 21 tracked investments across 11 companies. The latest tracked deal is $53.0M Series D in CSA Medical in September 2024.

Investments

11 companies

Investments Made

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Sep 1, 2024	CSA Medical	$53.0M Series D	TVM Capital, Yonjin Capital	Ascension Ventures, SV Health Investors
May 2, 2018	Rapid Micro Biosystems	$60.0M Other Equity	Jeff Schwartz, Fares Zahir	Asahi Kasei Medical, Longitude Capital, Quaker Partners
Apr 1, 2015	Rapid Micro Biosystems	$25.0M Series C	—	Apollo Health Ventures, Shawn LU, Kleiner Perkins, Longitude Capital, Quaker Partners, Richard King Mellon Foundation, Fred Cohen
May 16, 2014	Proteon Therapeutics	$45.0M Series D	TIM Haines	Bessemer Venture Partners, Deerfield Management, Devon Park Bioventures, Intersouth Partners, MPM Capital, Dmitry Kobyzev, Ph.d., Prism VentureWorks, Skyline Ventures, Vectis Healthcare And Life Sciences Fund
Nov 20, 2013	Argos Therapeutics	$17.5M Series E Extension	—	Aurora Funds, Forbion, Green Cross Holdings, Intersouth Partners, Lumira Ventures, Morningside, Pharmstandard International
Oct 1, 2013	F-Star Therapeutics	$9.0M Star Therapeutics - Series A	—	Atlas Venture, INKEF Capital, Aescap Venture, MP Healthcare Venture Management, MS Ventures, SR ONE
Aug 28, 2013	Argos Therapeutics	$42.5M Series E	Alexandr Shuster	Aurora Funds, Forbion, Green Cross Holdings, Intersouth Partners, Lumira Ventures, Morningside
Jun 1, 2013	Rapid Micro Biosystems	$33.0M Series B	David Hirsch, Mark Braganza	Apollo Health Ventures, Kleiner Perkins, Quaker Partners
Jul 1, 2012	Bluebird Bio	$60.0M Series D	—	ARCH Venture Partners, Third Rock Ventures, Howie Furst, Forbion, RA Capital Management, Ramius Capital Group, Shire
Apr 24, 2012	Argos Therapeutics	$25.0M Series D	Forbion	Aurora Funds, Intersouth Partners, Lumira Ventures, Morningside
Jan 4, 2012	Vivoryon Therapeutics	$19.4M Other Equity	—	BB Biotech, Biogen Idec NEW Ventures, Goodvent, HBM Healthcare Investments, LSP, Wellington Management
Apr 20, 2011	Bluebird Bio	$30.0M Other Equity II	—	Steven Gillis, Easton Capital, Forbion, Third Rock Ventures
Apr 1, 2011	Bluebird Bio	$30.0M Series C	—	ARCH Venture Partners, Third Rock Ventures, Easton Capital, Forbion
Oct 21, 2010	Abionyx Pharma	$14.0M Series C	Irdi Capital Investissement	Alta Partners, Daiwa Corporate Investment, EDF Ventures, HealthCap, OrbiMed, Sofinnova Partners, Strategic Investment Fund
Oct 12, 2010	TME Pharma	$2.8M Series D Extension	—	Sofinnova Partners, CD Venture, Dewb, Dieckell Group, IBB Ventures, IBG Sachsen Anhalt, NGN Capital, Oppenheim Asset Management Services, Seventure Partners, The DOW Chemical Company
Aug 20, 2010	Anchor Therapeutics	$10.0M Series B	HealthCare Ventures, Novartis, TVM Capital	—
Jul 1, 2010	Abionyx Pharma	$65.0M Series C	Jean Pierre Garnier	Soffinova Partners, Alta Partners, Daiwa Corporate Investment, EDF Ventures, HealthCap, OrbiMed
Jun 18, 2010	Precision Therapeutics	$35.0M Other Equity	Jeff Crisan	Adams Capital Management, Birchmere Ventures, Longitude Capital, Quaker Partners
May 1, 2010	TME Pharma	$41.0M Series D	NGN Capital	Andera Partners, Dieckell Group, FCP OP MEDICAL BioHealth Trends, IBB Ventures, IBG Sachsen Anhalt, Seventure Partners, Sofinnova Partners, The DOW Chemical Company
Jan 1, 2010	F-Star Therapeutics	$12.0M Star Therapeutics - Series A	MP Healthcare Venture Management, M Ventures	Atlas Venture, INKEF Capital, Aescap Venture, Novo Ventures
Nov 1, 2009	Vivoryon Therapeutics	$54.0M Series B	Dallas Webb	Andera Partners, Rossella Medori, CFH Group, HBM Healthcare Investments, IBG Sachsen Anhalt, Jörg Neermann